Cargando…
Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer
Acquisition of resistance to gemcitabine is a challenging clinical and biological hallmark property of refractory pancreatic cancer. Here, we investigated whether glycogen synthase kinase (GSK)‐3β, an emerging therapeutic target in various cancer types, is mechanistically involved in acquired resist...
Autores principales: | Uehara, Masahiro, Domoto, Takahiro, Takenaka, Satoshi, Bolidong, Dilireba, Takeuchi, Osamu, Miyashita, Tomoharu, Minamoto, Toshinari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734171/ https://www.ncbi.nlm.nih.gov/pubmed/32986894 http://dx.doi.org/10.1111/cas.14668 |
Ejemplares similares
-
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
por: Domoto, Takahiro, et al.
Publicado: (2020) -
Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma
por: Bolidong, Dilireba, et al.
Publicado: (2020) -
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma
por: Abe, Kensaku, et al.
Publicado: (2019) -
Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy
por: Domoto, Takahiro, et al.
Publicado: (2016) -
Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction
por: Dewi, Firli R.P., et al.
Publicado: (2018)